Response inhibition in Huntington's disease - A study using ERPs and sLORETA

被引:78
|
作者
Beste, Christian [1 ,2 ,3 ]
Saft, Carsten [2 ]
Andrich, Juergen [2 ]
Gold, Ralf [2 ]
Falkenstein, Michael [1 ]
机构
[1] WHO Collaborating Ctr, Occupat Hlth & Human Factors, Leibniz Res Ctr Working Environm & Human Factors, D-44139 Dortmund, Germany
[2] Ruhr Univ Bochum, St Josef Hosp, Huntington Ctr NRW, Dept Neurol, Bochum, Germany
[3] Univ Munster, Dept Clin Radiol, D-4400 Munster, Germany
关键词
Nogo-N2; Nogo-P3; sLORETA; dopamine; genetics; basal ganglia;
D O I
10.1016/j.neuropsychologia.2007.12.008
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Huntington's disease (HD) is an autosomal dominant inherited neurodegenerative disorder, with neurodegeneration mainly affecting the striatum. We investigated executive functions related to response inhibition in (HD) and healthy controls by means of event-related potentials (ERP) in a simple Go/Nogo-task. In Nogo as opposed to Go trials two fronto-central ERP components are elicited: the Nogo-N2 and Nogo-P3. These components are supposed to depend on (medial) prefrontal regions, especially the anterior cingulate cortex (ACC). The results show that the Nogo-N2 did not differ between the groups, while the Nogo-P3 demonstrated a strong attenuation in the HD-group, which also showed more false alarms in the Nogo-condition. Using sLORETA it is shown that this attenuation was related to the medial frontal cortex, especially the ACC, and superior frontal cortex areas. Moreover, the attenuation was related to the underlying genetic disease load (CAG-index). The decline in inhibition is likely mediated via a dysfunction in the ACC, which is known to be dysfunctional in HD. Moreover, the results may be interpreted that the decline in response inhibition in HD is gene-associated. The differentially affected Nogo-components suggest that they rely on different neuronal circuits, even within the ACC. For HD this suggests that this structure is not entirely dysfunctional. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1290 / 1297
页数:8
相关论文
共 50 条
  • [1] Brain compensation during response inhibition in premanifest Huntington's disease
    Soloveva, Maria, V
    Jamadar, Sharna D.
    Hughes, Matthew
    Velakoulis, Dennis
    Poudel, Govinda
    Georgiou-Karistianis, Nellie
    BRAIN AND COGNITION, 2020, 141
  • [2] ATTENTION AND INHIBITION IN HUNTINGTON'S DISEASE
    t'Hart, E.
    de Hiele, K. van
    Jurgens, C.
    Reijntjes, R.
    Middelkoop, H.
    Roos, R. A. C.
    van Dijk, G.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2010, 81 : A31 - A31
  • [3] ERPS TO RESPONSE PRODUCTION AND INHIBITION
    PFEFFERBAUM, A
    FORD, JM
    WELLER, BJ
    KOPELL, BS
    ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY, 1985, 60 (05): : 423 - 434
  • [4] Disruption of response inhibition circuits in prodromal Huntington disease
    Rao, Julia A.
    Harrington, Deborah L.
    Durgerian, Sally
    Reece, Christine
    Mourany, Lyla
    Koenig, Katherine
    Lowe, Mark J.
    Magnotta, Vincent A.
    Long, Jeffrey D.
    Johnson, Hans J.
    Paulsen, Jane S.
    Rao, Stephen M.
    CORTEX, 2014, 58 : 72 - 85
  • [5] Reduced frontal activity during response inhibition in individuals with psychopathic traits: An sLORETA study
    Kim, Young Youn
    Jung, Yoon Sun
    BIOLOGICAL PSYCHOLOGY, 2014, 97 : 49 - 59
  • [6] Prediction of Response to Cholinesterase Inhibitor Treatment in Alzheimer's Disease by Means of Sloreta
    Brunovsky, M.
    Krajca, V.
    Bartos, A.
    Diblikova, F.
    Vysata, O.
    NEUROPSYCHOBIOLOGY, 2008, 58 (3-4) : 238 - 238
  • [7] Predictors of response to tetrabenazine in Huntington's disease
    Marshall, F. J.
    Eberly, S.
    Frank, S.
    Oakes, D.
    MOVEMENT DISORDERS, 2006, 21 (09) : 1547 - 1547
  • [8] A Metabolic Study of Huntington's Disease
    Nambron, Rajasree
    Silajdzic, Edina
    Kalliolia, Eirini
    Ottolenghi, Chris
    Hindmarsh, Peter
    Hill, Nathan R.
    Costelloe, Sean J.
    Martin, Nicholas G.
    Positano, Vincenzo
    Watt, Hilary C.
    Frost, Chris
    Bjorkqvist, Maria
    Warner, Thomas T.
    PLOS ONE, 2016, 11 (01):
  • [9] Huntington's disease - case study
    Adamczak-Ratajczak, Agnieszka
    Szumerowicz, Lukasz
    Krawczyk, Mieczyslaw
    Madry, Edyta
    FAMILY MEDICINE AND PRIMARY CARE REVIEW, 2011, 13 (02): : 357 - 358
  • [10] Intracortical inhibition and facilitation are abnormal in Huntington's disease: A paired magnetic stimulation study
    Abbruzzese, G
    Buccolieri, A
    Marchese, R
    Trompetto, C
    Mandich, P
    Schieppati, M
    NEUROSCIENCE LETTERS, 1997, 228 (02) : 87 - 90